UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
   
FORM 8-K
 
  CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 11, 2017
 
  Roka Bioscience, Inc.
(Exact name of registrant as specified in its charter)
   
 
 
 
 
 
 
Delaware
 
001-36538
 
27-0881542
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(I.R.S. Employer
Identification No.)
 
 
 
 
20 Independence Boulevard
Warren, NJ
 
07059
(Address of principal executive offices)
 
(Zip Code)
Registrant’s telephone number, including area code
(908) 605-4700
Not Applicable
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐





If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 2.02. Results of Operations and Financial Condition.
On May 11, 2017 , Roka Bioscience, Inc. (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2017 . A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.
The information in this Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No.
  
Description
99.1
  
Press release issued by Roka Bioscience, Inc. dated May 11, 2017, furnished hereto.





SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
 
 
 
May 11, 2017
 
 
 
ROKA BIOSCIENCE, INC.
 
 
 
 
 
 
 
 
By:
 
/s/ Lars Boesgaard
 
 
 
 
 
 
Lars Boesgaard
 
 
 
 
 
 
Vice President and Chief Financial Officer






EXHIBIT INDEX
 
Exhibit
No.
  
Description
99.1
  
Press release issued by Roka Bioscience, Inc. dated May 11, 2017, furnished hereto.



ROKA BIOSCIENCE, INC. (NASDAQ:ROKA)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more ROKA BIOSCIENCE, INC. Charts.
ROKA BIOSCIENCE, INC. (NASDAQ:ROKA)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more ROKA BIOSCIENCE, INC. Charts.